Report COM (2025) 392 outlines several advances in the implementation of the EU Global Health Strategy: financial contributions to Gavi, the Global Fund, and the Pandemic Fund; strengthened European preparedness capacities; and enhanced policy synergies through “Health in All Policies” and the Team Europe approach. However, concerns persist regarding sustainable financing, effective coordination among Member States, and the concrete assessment of impact.

Starting August 2, 2025, the European AI Act enforces rules for general-purpose AI models, requiring transparency and safety for high-risk applications such as those in the pharmaceutical sector. America’s AI Action Plan prioritizes innovation. Companies will need to strike a balance between compliance and agility.

Genenta announces Long-Term follow-up observations in brain tumor (GBM) study with emerging survival signals

BSI, full-scope Notified Body for all three types of devices pursuant to MDR and IVDR, is able to offer verification services for compliance with European directives about the production of medical devices

In the March multimedia magazine, we explore the impact of artificial intelligence and cybersecurity regulations in the pharmaceutical industry. As artificial intelligence reshapes drug development,...

This special issue explores the impact of automation and AI on pharmaceutical production—across GxP, sustainability, and digitalization.